MaxLinear (MXL) has had the highest return since March 27, 2026 by a mid-cap US stock, returning 293.3%.
| ASSET | % RETURN |
|---|---|
MaxLinear (MXL) | 293.31% |
P3 Health Partners (PIII) | 276.19% |
Abcellera Biologics (ABCL) | 262.84% |
Aehr Test Systems (AEHR) | 214.57% |
Uniqure (QURE) | 213.57% |
10X Genomics (TXG) | 209.87% |
Twist Bioscience (TWST) | 205.62% |
Penguin Solutions (PENG) | 204.31% |
Amylyx Pharmaceuticals (AMLX) | 187.2% |
Hemab Therapeutics Holdings, Inc Common Stock (COAG) | 187% |
Sellas Life Sciences (SLS) | 186.16% |
SharonAI Holdings, Inc Class A Common Stock (SHAZ) | 182.84% |
UroGen Pharma (URGN) | 180.95% |
Maase (MAAS) | 180.46% |
Oscar Health (OSCR) | 175.36% |
CareDx (CDNA) | 168.22% |
AMC Entertainment (AMC) | 159.79% |
BlackBerry (BB) | 156.62% |
Oruka Therapeutics (ORKA) | 143.65% |
Definium Therapeutics (DFTX) | 143.34% |
MBX Biosciences, Inc Common Stock (MBX) | 141.35% |
Travere Therapeutics (TVTX) | 138.81% |
Maravai Lifesciences Holdings (MRVI) | 135.95% |
Clover Health Investments (CLOV) | 135.75% |
Crinetics Pharmaceuticals (CRNX) | 133.43% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.